[시장보고서]두경부암 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 약물 종류별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

두경부암 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 약물 종류별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Head and Neck Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region and Competition, 2020-2030F

상품코드 : 1692312

리서치사 : TechSci Research

발행일 : 2025년 03월

페이지 정보 : 영문 185 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,497,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,940,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,550,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계 두경부암 치료제 시장은 2024년 19억 5,000만 달러로 평가되며, 예측 기간 동안 연평균 성장률(CAGR) 6.11%로 성장하여 2030년에는 27억 5,000만 달러에 달할 것으로 예상됩니다.

암은 여전히 전 세계 수백만 명의 생명을 앗아가는 세계 보건의 큰 문제입니다. 여러 종류의 암 중에서도 두경부암은 특히 복잡하고 치료가 어려운 암입니다. 구강, 인두, 후두, 부비동, 비강에 발생하는 종양을 포함하며, 환자의 삶의 질에 심각한 영향을 미치기 때문에 전문적인 치료가 필요합니다. 세계 두경부암 치료제 시장은 혁신적인 치료 솔루션을 제공함으로써 이 의료 문제를 해결하는 데 중요한 역할을 하고 있습니다. 이 암은 입, 목, 성대, 부비동, 침샘 등 상부 호흡기 및 소화관의 여러 부위에서 발생합니다. 알려진 위험인자로는 담배와 알코올 사용, 인유두종 바이러스(HPV) 감염, 다양한 화학제품 및 자극 물질에 대한 노출 등이 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	19억 5,000만 달러
시장 규모 : 2030년	27억 5,000만 달러
CAGR : 2025-2030년	6.11%
급성장 부문	면역요법
최대 시장	북미

두경부암 치료제 시장은 치료 성과의 개선과 환자의 삶의 질 향상을 위한 지속적인 연구개발이 시장을 견인하고 있습니다. 시장 성장에 기여하는 주요 요인은 HPV 감염으로 인한 두경부암 발병률의 증가, 특히 젊은 층의 발병률 증가입니다. 생존율 향상을 위해서는 조기 발견과 효과적인 치료가 필수적입니다. 정밀의료, 면역치료 등 의료기술의 발달로 보다 효과적이고 부작용이 적은 표적치료와 개인별 맞춤 치료계획이 개발되고 있습니다. 수술, 화학요법, 방사선 치료와 같은 전통적인 치료법은 면역요법(체크포인트 억제제 등)과 표적 치료제(EGFR 억제제 등)와 같은 새로운 대안으로 보완되고 있습니다.

주요 시장 촉진요인

두경부암의 발병률 증가

주요 시장 과제:

높은 발병률

주요 시장 동향:

기술 발전

영문목차

The global Head and Neck Cancer Drugs Market was valued at USD 1.95 billion in 2024 and is projected to reach USD 2.75 billion by 2030, with a compound annual growth rate (CAGR) of 6.11% during the forecast period. Cancer remains a significant global health challenge, affecting millions of lives worldwide. Among the various cancer types, head and neck cancer is particularly complex and difficult to treat. It includes tumors that develop in the oral cavity, pharynx, larynx, paranasal sinuses, and nasal cavity, and can severely impact patients' quality of life, requiring specialized treatments. The global head and neck cancer drugs market plays a critical role in addressing this medical issue by providing innovative therapeutic solutions. This cancer type affects several components of the upper respiratory and digestive tracts, including the mouth, throat, voice box, sinuses, and salivary glands. Known risk factors include tobacco and alcohol use, human papillomavirus (HPV) infection, and exposure to various chemicals and irritants.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.95 Billion
Market Size 2030	USD 2.75 Billion
CAGR 2025-2030	6.11%
Fastest Growing Segment	Immunotherapy
Largest Market	North America

The head and neck cancer drugs market is driven by ongoing research and development efforts aimed at improving treatment outcomes and enhancing patient quality of life. A key factor contributing to market growth is the rising incidence of head and neck cancer, particularly among younger individuals due to HPV infections. Early detection and effective treatment are essential for improving survival rates. Advances in medical technologies, such as precision medicine and immunotherapy, have led to the development of targeted therapies and personalized treatment plans, which are more effective and have fewer side effects. Traditional treatments like surgery, chemotherapy, and radiation therapy are being supplemented by newer options, such as immunotherapies (e.g., checkpoint inhibitors) and targeted therapies (e.g., EGFR inhibitors).

Key Market Drivers:

Increasing Incidence of Head and Neck Cancer

Head and neck cancer is a complex group of diseases that affect the oral cavity, throat, larynx, and nasal passages. This type of cancer significantly impacts patients' quality of life and has been steadily increasing in incidence worldwide. According to Global Cancer Statistics, head and neck cancer ranks as the third most common cancer globally, with 1.46 million new cases and 487,993 deaths, accounting for 7.6% of all cancer cases and 4.8% of cancer-related deaths globally. This growing burden, coupled with advancements in cancer treatments, is driving demand for innovative therapies. The market for head and neck cancer drugs is anticipated to experience significant growth as the healthcare sector prioritizes cancer care and patients increasingly seek effective treatment options. Risk factors for head and neck cancer include tobacco and alcohol use, HPV infection, and certain dietary habits. While smoking rates have declined, leading to a decrease in cancers related to the larynx, the rise in oropharyngeal cancers linked to HPV infection remains a concern.

Key Market Challenges:

High Incidence Rates

One of the primary challenges faced by the head and neck cancer drugs market is the high incidence of the disease. With cancers affecting the mouth, throat, and larynx among the most prevalent globally, the increased number of cases places significant pressure on healthcare systems. This rising incidence fuels demand for more effective treatments and medications.

Key Market Trends:

Technological Advancements

Technological advancements are playing a pivotal role in improving the diagnosis, treatment, and prognosis of head and neck cancer. These innovations are not only enhancing patient outcomes but also stimulating market growth. High-resolution imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) allow healthcare providers to detect and assess head and neck cancers with greater accuracy, facilitating early detection and timely intervention. Additionally, advances in genomics and proteomics have led to the identification of specific biomarkers associated with head and neck cancer. Biomarker-based tests enable early diagnosis and help develop personalized treatment plans tailored to individual patients. Telemedicine has also revolutionized healthcare delivery, allowing remote consultations and pathology reviews. This is especially important for head and neck cancer, as it enables specialists to provide expertise and collaborate in underserved or remote regions.

Key Market Players:

Merck & Co., Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
AstraZeneca Plc.
Fresenius Medical Care AG & CO. KGAA
F. Hoffmann-La Roche Ltd.

Report Scope:

This report segments the Global Head and Neck Cancer Drugs Market into the following categories, in addition to providing insights into industry trends:

By Drug Class:

Chemotherapy
Immunotherapy
Targeted Therapy

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region:

North America: United States, Canada, Mexico
Europe: France, United Kingdom, Italy, Germany, Spain
Asia Pacific: China, India, Japan, Australia, South Korea
South America: Brazil, Argentina, Colombia
Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape:

This section includes detailed analysis and profiles of major companies operating in the Head and Neck Cancer Drugs Market.

Available Customizations:

TechSci Research offers customization options for this market report, allowing adjustments based on specific company needs. Customization options include the profiling of additional market players (up to five).

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Head and Neck Cancer Drugs Market

5. Global Head and Neck Cancer Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Class (Chemotherapy, Immunotherapy, Targeted Therapy)
- 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. Asia Pacific Head and Neck Cancer Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Distribution Channel
- 6.2.3. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Head and Neck Cancer Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Class
    - 6.3.1.2.2. By Distribution Channel
- 6.3.2. India Head and Neck Cancer Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Class
    - 6.3.2.2.2. By Distribution Channel
- 6.3.3. Australia Head and Neck Cancer Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Class
    - 6.3.3.2.2. By Distribution Channel
- 6.3.4. Japan Head and Neck Cancer Drugs Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Drug Class
    - 6.3.4.2.2. By Distribution Channel
- 6.3.5. South Korea Head and Neck Cancer Drugs Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Drug Class
    - 6.3.5.2.2. By Distribution Channel

7. Europe Head and Neck Cancer Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Distribution Channel
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Head and Neck Cancer Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Class
    - 7.3.1.2.2. By Distribution Channel
- 7.3.2. Germany Head and Neck Cancer Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Class
    - 7.3.2.2.2. By Distribution Channel
- 7.3.3. Spain Head and Neck Cancer Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Class
    - 7.3.3.2.2. By Distribution Channel
- 7.3.4. Italy Head and Neck Cancer Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Class
    - 7.3.4.2.2. By Distribution Channel
- 7.3.5. United Kingdom Head and Neck Cancer Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Class
    - 7.3.5.2.2. By Distribution Channel

8. North America Head and Neck Cancer Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Distribution Channel
- 8.2.3. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Head and Neck Cancer Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Class
    - 8.3.1.2.2. By Distribution Channel
- 8.3.2. Mexico Head and Neck Cancer Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Class
    - 8.3.2.2.2. By Distribution Channel
- 8.3.3. Canada Head and Neck Cancer Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Class
    - 8.3.3.2.2. By Distribution Channel

9. South America Head and Neck Cancer Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Distribution Channel
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Head and Neck Cancer Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Class
    - 9.3.1.2.2. By Distribution Channel
- 9.3.2. Argentina Head and Neck Cancer Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Class
    - 9.3.2.2.2. By Distribution Channel
- 9.3.3. Colombia Head and Neck Cancer Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Class
    - 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Head and Neck Cancer Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Distribution Channel
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Head and Neck Cancer Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Class
    - 10.3.1.2.2. By Distribution Channel
- 10.3.2. Saudi Arabia Head and Neck Cancer Drugs Market Outlook
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Class
    - 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Head and Neck Cancer Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Class
    - 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Head and Neck Cancer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. Competitive Landscape

15.1. Merck & Co., Inc.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
15.2. Eli Lilly and Company
15.3. Bristol-Myers Squibb Company
15.4. Astrazeneca Plc.
15.5. Fresenius Medical Care AG & CO. KGAA
15.6. F.Hoffmann-la Roche Ltd.

한글목차

주요 시장 촉진요인

주요 시장 과제:

주요 시장 동향:

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 두경부암 치료제 시장에 미치는 영향

제5장 세계의 두경부암 치료제 시장 전망

제6장 아시아태평양의 두경부암 치료제 시장 전망

제7장 유럽의 두경부암 치료제 시장 전망

제8장 북미의 두경부암 치료제 시장 전망

제9장 남미의 두경부암 치료제 시장 전망

제10장 중동 및 아프리카의 두경부암 치료제 시장 전망

제11장 시장 역학

제12장 시장 동향과 발전

제13장 세계의 두경부암 치료제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

제15장 경쟁 구도

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항